22CM
UBX

20/20 Capital Management’s Unity Biotechnology UBX Stock Holding History

20/20 Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$199K Buy
+4,284
New +$206K 0.05% 165

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

20/20 Capital Management's UBX Position: Q2 2021 in Review

20/20 Capital Management opened a new position in Unity Biotechnology (UBX) in Q2 2021: 4,284 shares worth $199K. The stake represents 0.05% of the portfolio and ranks #165 among its holdings.

98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

  • 20/20 Capital Management held 4,284 shares of Unity Biotechnology worth $199K as of Q2 2021.
  • Unity Biotechnology was a new 20/20 Capital Management position in Q2 2021.
  • Unity Biotechnology made up 0.05% of 20/20 Capital Management's portfolio in Q2 2021, its #165 holding.
  • 98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on 20/20 Capital Management's 13F filing for Q2 2021, filed 12 Jul 2021.